Relay Therapeutics CFO Sells 17,717 Shares for $350,000
Catinazzo's pre-arranged sale reduced his direct stake by 11%, but the insider still holds a significant amount of shares.
Overview
Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics (NASDAQ:RLAY), sold 17,717 shares of common stock on Aug. 14, 2026, according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($19.74); post-transaction value based on Aug. 14, 2026, market close ($19.86).
Details
Relay Therapeutics is a clinical-stage precision medicine company with a market capitalization of $4 billion, headquartered in Cambridge and employing more than 200 people. The company has demonstrated significant momentum, with shares appreciating 485% over the past year around the time of the transaction, reflecting investor confidence in its drug development pipeline. As a pre-revenue stage biotechnology enterprise, Relay's competitive positioning depends on the clinical efficacy and regulatory pathway of its small molecule candidates, particularly RLY-4008, which addresses underserved oncology indications with differentiated mechanisms of action.
Source
Originally published at www.fool.com.